反氧化活性氧化物增强了西斯普拉丁对宫癌的疗效
Carl P Soltau1, Debottam Sinha2, Lakshita P Patil2
1School of Chemistry and Physics, Queensland University of Technology, 2 George St, Brisbane, QLD, 4000, Australia; Cancer & Ageing Research Program, Centre for Genomics and Personalised Health, Queensland University of Technology, 60 Musk Ave, Kelvin Grove, QLD, 4059, Australia.
Redox biology
|January 7, 2026
概括
新型类固醇化合物 (CS91,CS187) 通过增加活性氧物种 (ROS) 和DNA损伤来增强宫癌的西斯普拉丁化疗,提供了一个有希望的向治疗策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 西斯是一种主要的宫癌治疗方法,但其疗效受到毒性和抗化学物质的限制.
- 葡萄糖皮质体受体 (GR) 过度表达和改变的细胞氧化还原状态有助于宫癌的化学抵抗.
研究的目的:
- 探索基于类固醇和氧化物的新疗法与西斯普拉丁结合,以克服宫癌中的化学抵抗.
- 为了确定可以提高西斯普拉丁疗效的化合物,同时最大限度地降低毒性.
主要方法:
- 合成并鉴定出两种氧化功能化的普雷迪尼索隆杂交物 (CS91和CS187).
- 评估了CS91和CS187.7的抗扩散活性和GR结合能力.
- 评估了CS91和CS187与西斯普拉丁结合对宫癌细胞系的疗效.
- 调查了潜在的机制,包括活性氧物种 (ROS),谷氨 (GSH) 水平和DNA损伤.
主要成果:
- CS91和CS187在状状细胞癌 (SCC) 线中表现出强大的抗增殖活性,与原生氧化物相似,同时保持GR结合.
- 将CS91/CS187与西斯胺结合使用,显著降低了癌细胞活力 (<15%),同时保持了健康细胞活力 (>80%).
- 与单独使用西斯相比,组合疗法协同增加了细胞内ROS水平,降低了GSH水平,并增强了DNA损伤.
结论:
- 基于氧化物的混合物 (CS91,CS187) 对宫癌具有强大的抗增殖作用.
- 这些混合物通过ROS介导的机制增强西斯丁的疗效,这代表了宫癌治疗的有希望的有针对性的策略.
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
564
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
564
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
01:46Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
594
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
594